• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Enable Injections adds finance veteran to its board

November 7, 2023 By Sean Whooley

Vickie Capps Enable Injections NuVasive
New Enable Injections board member Vickie Capps. [Image from
NuVasive]
Enable Injections announced today that it appointed Vickie Capps to its board of directors as the head of the audit committee.

Capps joins the wearable drug delivery system maker with plenty of experience in finance and executive leadership. She also brings extensive board experience, including currently serving on the board of orthopedic company NuVasive.

Other boards Capps serves on include Amedisys and Janux Therapeutics. She serves as a member of the senior advisory board at Consonance Capital Partners, a healthcare-focused private equity firm. Her record includes serving as CFO of DJO Global from 2002 to 2013 as well.

Capps joins the board of Enable Injections at a good time. The company just picked up FDA approval for its enFuse injector for the delivery of Empaveli.

“The enFuse technology could make a significant impact on the drug delivery industry and how patients receive life-altering medication,” said Capps. “I’m excited to be part of this innovative company and I look forward to working with the team on increasingly meaningful milestones in the future.”

Capps’ appointment increases the size of the Enable Injections board to 10 members. The board features a wide range of business, pharmaceutical and medical device backgrounds.

“Vickie brings a wealth of experience and financial acumen to our board at a pivotal stage for Enable Injections,” said Mike Hooven, chair and CEO of Enable Injections. “Her expertise in global business operations, corporate finance and accounting, capital markets, and investor relations will help to drive Enable forward as we enter the next phase of commercialization as a company. We are thrilled to welcome her to the Enable team.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: Enable Injections, Personnel Moves

IN CASE YOU MISSED IT

  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM
  • Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan
  • Abbott sets Libre Duo glucose-ketone sensor US launch for December
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS